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BACKGROUND: Immunosuppression and Merkel-cell polyomavirus (MCPyV) infection may have a role in the pathogenesis of Merkel-
cell carcinoma (MCC), a rare neuroendocrine carcinoma of the skin.
METHODS: We studied incidence of chronic lymphocytic leukaemia (CLL) and MCC from the files of the Finnish Cancer Registry and
the largest hospital of Finland, Helsinki University Central Hospital, from 1979 to 2006. Presence of MCPyV DNA in MCCs was
investigated by quantitative PCR.
RESULTS: We identified 4164 patients diagnosed with CLL and 172 diagnosed with MCC. Six patients diagnosed with both diseases
were found; CLL was the first diagnosis in four cases and MCC in two. The standardised incidence ratio (SIR) for CLL after the
diagnosis of MCC was highly elevated, 17.9 (95% confidence interval (CI), 2.2–64.6; Po0.001), and the SIR for MCC after the
diagnosis of CLL was also elevated, 15.7 (3.2–46.0, Po0.01). Merkel-cell polyomavirus DNA was present in all five MCCs with
tumour tissue available for analysis.
CONCLUSIONS: We conclude that patients diagnosed with CLL have a substantially increased risk for MCC, and vice versa. Merkel-cell
polyomavirus DNA is frequently present in MCCs that occur in CLL patients. Immunosuppression related with CLL and viral infection
might explain the association between CLL and MCC.
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Merkel-cell carcinoma (MCC) is a rare neuroendocrine carcinoma
of the skin. In one study based on the surveillance, epidemiology,
and end results (SEER) program registry of the United States, the
annual incidence of MCC increased from 1.5 cases per million in
1986 to 4.4 cases per million in 2001 (Hodgson, 2005). The age-
specific incidence was the highest in the elderly Caucasian
population (Agelli and Clegg, 2003; Hodgson, 2005). Only a small
proportion of MCCs occur before the age of 50.
Most MCCs are found in the sun-exposed skin of the head and
neck or the extremities (Poulsen, 2005). Merkel-cell carcinoma
usually presents with a non-tender, rapidly growing red/pink or
blue/violaceous skin lesion. The median time from the lesion
appearance to a biopsy is approximately 3 months (Heath et al,
2008). Patients diagnosed with localised, regional, and distant
MCC have a 5-year relative survival of 75%, 59%, and 25%,
respectively (Agelli and Clegg, 2003). Few patients diagnosed with
distant metastases survive for 3 years or longer (Allen et al, 2005).
Merkel-cell carcinoma has been linked with immunosuppres-
sion related to various conditions, such as AIDS, organ
transplantation, and presence of chronic lymphocytic leukaemia
(CLL; Quaglino et al, 1997; Ziprin et al, 2000; Sinclair et al, 2003;
Howard et al, 2006; Heath et al, 2008). The suggested association
between CLL and MCC was based largely only on small single-
centre series and case reports, until Howard et al (2006), using the
SEER database, found patients diagnosed with MCC to have a
standardised incidence ratio (SIR) of 2.7 for a subsequent
diagnosis of CLL (95% confidence interval (CI), 0.55–7.9), and
reciprocally, patients diagnosed with CLL to have a SIR of 6.9 (95%
CI, 3.8 to 11.6) for a subsequent MCC. Recently, Heath et al (2008)
suggested a considerably stronger association, estimating that CLL
is more than 30-fold overrepresented among patients diagnosed
with MCC based on a joint series of five institutes from Boston and
Seattle.
DNA of a novel virus, named as Merkel-cell polyomavirus
(MCPyV), was recently detected in the majority of MCCs
investigated (Feng et al, 2008). The viral DNA was found in eight
out of the 10 MCCs studied, and in most cases the viral DNA was
integrated within the tumour genome in a clonal pattern. Patients
whose MCC contained MCPyV DNA were subsequently found to
have substantially more favourable survival than those whose
cancer did not contain MCPyV DNA, and MCPyV-positive cancers
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swere more frequently located in the limbs (Sihto et al, 2009). These
clinical associations lend further support to a hypothesis that viral
infection may be an early event in the molecular pathogenesis of
MCC.
We investigated in the present study whether the association
between CLL and MCC is reciprocal and calculated the strength of
this association using the files of Finnish Cancer Registry. Nothing
is known about the presence of MCPyV DNA in MCCs that occur
in individuals diagnosed also with CLL. Therefore, we studied the
MCCs for MCPyV DNA using quantitative PCR.
PATIENTS AND METHODS
The nationwide population-based Finnish Cancer Registry,
founded in 1952, covers the entire Finnish population (5.3 million
in 2009). Hospitals, practicing physicians, and pathological and
haematological laboratories are requested to report to the Finnish
Cancer Registry all cases of cancer that come to their attention. In
addition, each year, data of all death certificates that mention
cancer are transferred to the Registry. Deaths and emigrations are
registered in the Central Population Register and are regularly
linked to the Finnish Cancer Registry. The Registry has coverage
exceeding 99% (Teppo et al, 1994).
The study cohort includes all persons who were diagnosed with
MCC in Finland from 1979 to 2006, and who were registered in the
files of the Finnish Cancer Registry. All diagnoses of MCC in the
Registry were based on histological examination. The follow-up for
the subsequent primary neoplasm (either MCC or CLL) started
from the date of the diagnosis of the first cancer (either MCC or
CLL), and ended at the time of death, emigration, or the closing
date of the study (December 31, 2006), whichever was earliest. The
observed numbers of cancers and person–years at risk were
tabulated by sex, 5-year age group, and the calendar period. The
expected numbers of cancer were obtained by multiplying the
stratum-specific numbers of person–years by the corresponding
cancer incidence rates in Finland. The SIRs were calculated by
dividing the observed numbers of cancer by the expected ones.
Exact 95% CIs were calculated assuming that the numbers of
observed cases followed a Poisson distribution.
Data on patient and tumour characteristics, course of the
disease, treatments administered, and outcome were retrieved
from hospital case records of the patients recorded as diagnosed
with both MCC and CLL during their lifetime. Formalin-fixed,
paraffin-embedded tissue blocks of MCC tumours were retrieved
from the pathology archives. The MCC diagnoses were confirmed
in a blinded manner by two researchers with a special expertise in
MCC pathology (T Bo ¨hling and H Kukko). The samples were
stained with haematoxylin and eosin, and we performed im-
munohistochemistry with antibodies for cytokeratin-20 (CK-20;
DakoCytomation, Glostrup, Denmark) and thyroid transcription
factor-1 (TTF-1; Novocastra, Newcastle Upon Tyne, UK) to
confirm the diagnosis of MCC. For histological diagnosis of
MCC, it was required for tissue morphology to be compatible with
MCC in microscopy, and that the cancer cells stained positively for
CK-20 and negatively for TTF-1. The longest diameter of the
tumour was measured from haematoxylin and eosin-stained slides,
and in case of a large tumour the diameter reported in the hospital
case records was accepted. The diagnosis of CLL was based on the
original analyses of the bone marrow and the peripheral blood
samples, and we accepted the diagnosis of CLL as recorded in the
patients’ hospital files.
Presence of MCPyV DNA was analysed from DNA extracted
from representative deparaffinised tumour sections (patients 1, 2,
3, 4 and 6; Table 1) as described in a detail elsewhere (Sihto et al,
2009). In one case (patient 5) adequate tissue was not available for
MCPyV DNA detection. Quantitation of MCPyV DNA was
performed using real-time PCR with hydrolysis probes and
primers specific for the viral LT3 coding region with a LightCycler
480 instrument (Roche Diagnostics GmbH, Mannheim, Germany).
The relative DNA sequence copy number for each tissue sample
was expressed as a ratio of MCPyV DNA-to-protein tyrosine
phosphatase gamma receptor gene (PTPRG) DNA. Whenever
MCPyV DNA was detected (i.e., when the MCPyV DNA-to-PTPRG
DNA-ratio was greater than 0), the sample was considered positive.
Each PCR product generated was treated with an ExoSAP-IT
enzyme mix (product number 78201; USB Corporation, Cleveland,
OH, USA) according to the manufacturer’s instructions and then
sequenced using BigDye3 termination chemistry and an ABI 3100
Genetic Analyzer (both from Applied Biosystems, Foster City, CA,
USA). The sequences were compared with the reference sequences
of MCPyV isolates obtained from the National Center for
Biotechnology Information (NCBI) Entrez Nucleotide database
by using LaserGene 7.2 software (DNASTAR Inc., Madison, WI,
USA).
An institutional Ethics Committee approved the study protocol,
and permission to analyse the tissue samples was obtained from
the National Agency for Medicolegal Affairs, Finland.
RESULTS
Merkel-cell carcinoma following diagnosis of CLL
According the files of the Finnish Cancer Registry, a total of 4164
individuals were diagnosed with CLL in Finland from 1979 to 2006.
The follow-up yielded 19,809 person–years at risk. Altogether, in
this cohort three cases of MCC were identified after the diagnosis
of CLL corresponding to an SIR of 15.7 (95% CI, 3.2–46.0;
Po0.01). The time interval from the date of diagnosis of CLL to
the date of diagnosis of MCC varied from 0.2 to 9.6 years (median,
6.9 years).
In addition, one further patient diagnosed with MCC and
who had CLL in history (patient no. 6; Table 1) was identified
from the files of the Helsinki University Central Hospital.
The patient was initially diagnosed with lymphocytic lymphoma,
Table 1 Characteristics of patients and cancers, and clinical outcome
Patient
Gender/
age
a
Order of
presentation
Time
interval
(years) MCC site
MCC size/
regional
metastases
Presence of
MCPyV DNA in
MCC
Treatment
of MCC
Treatment
of CLL Outcome
Duration
of follow-up
(years)
b
1 F/92 MCC first 0.8 Lower arm 1.8cm/No Yes Excision None Died of CLL 0.8
2 F/70 MCC first 0.9 Thigh 3.0cm/No Yes Excision, flap, RT Fludarabine, prednisone Alive 5.2
3 F/63 CLL first 7.8 Upper arm 1.1cm/No Yes Excision None Died of CLL 0.1
4 M/77 CLL first 9.6 Hand 1.0cm/Yes Yes Excision Chorambucil, prednisone Died of CLL 2.1
5 F/81 CLL first 6.0 Chin 0.4cm/No NA Excision Fludarabine Died of CLL 5.7
6 M/79 CLL first
c 0.2 Thigh 2.0cm/Yes Yes Excision flap Chlorambucil Died of CLL 0.9
Abbreviations: CLL¼chronic lymphocytic leukaemia; F¼female; M¼male; MCC¼Merkel cell carcinoma; MCPyV¼Merkel-cell polyomavirus; NA¼not available;
RT¼radiation therapy.
aAt the time of diagnosis of MCC.
bCalculated from the date of diagnosis of MCC.
cThe initial diagnosis was well-differentiated lymphocytic lymphoma.
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sa disease almost identical to CLL, both morphologically and
clinically. An autopsy report confirmed CLL as the underlying
cause of death. This patient was not included in the calculation
of the SIR.
Chronic lymphocytic leukaemia following diagnosis of
MCC
A total of 172 patients were diagnosed with MCC in Finland from
1979 to 2006, according to the files of the Finnish Cancer Registry.
The follow-up yielded 713 person–years at risk. Before January 1
2007, 108 patients had died. In this cohort, two patients were
diagnosed with CLL after the diagnosis of MCC, producing an SIR
of 17.9 (95% CI 2.2–64.6; Po0.05). Both individuals were
diagnosed with CLL within 1 year after diagnosis of MCC (Table 1).
Search of the files of the Helsinki University Central Hospital did
not identify further cases.
Tumour characteristics and outcome
The demographic features of the patients, tumour characteristics,
treatments given, and outcome data of the patients are sum-
marised in Table 1. All patients were Caucasian, four were female,
and the mean age at the time of the MCC diagnosis was 77 years
(range, 63–92). Five out of the six tumours were located in an
extremity. The mean tumour diameter was 1.6cm (range, 0.4–
3.0cm). Three of the six patients had yet another malignancy
besides MCC and CLL in history (breast cancer, colon cancer, and
squamous-cell skin cancer, one of each).
Five of the six patients were considered to have died from CLL
and none from MCC. One patient had several local recurrences of
MCC, and in two cases MCC gave rise to regional lymph-node
metastases in the axilla or the groin.
Presence of MCPyV DNA in MCC
DNA for analysis of presence of MCPyV DNA was available in five
out of the six MCCs detected in a patient diagnosed also with CLL.
MCPyV DNA was present in all five analysed carcinomas (Table 1).
The copy numbers of MCPyV DNA ranged from 0.88 to 444.4
(median, 5.49) relative to the control gene (PTPRG) DNA copy
number. The MCPyV-positive tumours were all located in a limb.
DISCUSSION
The study showed remarkably strong and reciprocal association
between CLL and MCC. The SIR for a diagnosis of MCC following
the diagnosis of CLL was 15.7, and the SIR for the diagnosis of CLL
after the diagnosis of MCC was 17.9. The two patients diagnosed
with CLL following the diagnosis of MCC had the diagnosis made
within 1 year from the diagnosis of MCC, suggesting that CLL may
have been present already at the time of the diagnosis of MCC
considering the usually long natural history of CLL.
These SIRs are in line with the results of the Boston–Seattle
study, where CLL was estimated to be 30-fold overrepresented
among MCC patients (Heath et al, 2008). Merkel-cell carcinoma is
particularly common in the elderly Caucasian populations, and
incidence of MCC may change substantially with time (Hodgson,
2005), which may, in part, explain differences in the ratios
reported. Assuming an annual incidence of 4 per million
(Hodgson, 2005), a 20- to 30-fold SIR in a patient population
diagnosed with CLL translates to approximately 1 case per 10,000
patient–years.
Prolonged immunosuppression due to an underlying disease
such as CLL or HIV infection, or to iatrogenic immunosuppres-
sion, likely predisposes to MCC (Penn, 1993; Manganoni et al,
2007). Anticancer drugs used to treat CLL, such as chlorambucil
and fludarabine, may contribute to immunosuppression (Dighiero
et al, 1998; Rashid et al, 2005). The link between immunosuppres-
sion and MCC may be MCPyV infection (Feng et al, 2008),
although conclusive evidence for a causative role of MCPyV for
MCC is still lacking. We recently detected MCPyV DNA in 79.8% of
114 MCCs diagnosed in Finland (Sihto et al, 2009), which is a
slightly larger proportion than 72.3% detected in five smaller
studies that included a total of 148 MCCs (Feng et al, 2008;
Foulongne et al, 2008; Garneski et al, 2008; Kassem et al, 2008;
Becker et al, 2009; Sihto et al, 2009). Despite the small numbers,
the current finding of presence of MCPyV DNA in all MCCs among
the patients who were also diagnosed with CLL suggests a role for
MCPyV infection in the molecular pathogenesis of MCC in
immunocompromised patients. This hypothesis is supported by
the recent findings by Kassem et al (2009) who detected MCPyV
DNA more often in Bowen’s disease lesions and in basal-cell
carcinomas of the skin of immunocompromised patients as
compared with similar lesions detected in individuals with
apparently normal immune functions.
We did not have access to tissue or blood samples to assess the
presence of MCPyV in the bone marrow or in the circulating white
blood cells at the time of diagnosis of CLL, which is a limitation of
the study. Hypothetically, immunosuppression related to CLL or
its treatments might lead to MCPyV activation and subsequent
genesis of MCC, and despite the reciprocal association between
CLL and MCC, MCPyV might not have a major role in the
molecular pathogenesis of CLL. In line with this, MCPyV DNA was
recently found to be present only rarely and at low concentrations
in human haematological malignancies (Shuda et al, 2009). The
rates of MCPyV infection may also vary in different populations
(Garneski et al, 2009), which may influence the frequency of MCC
in patients diagnosed with CLL.
We conclude that patients diagnosed with CLL have a greatly
elevated risk for being diagnosed with MCC, and vice versa, as
compared with the general population. Due to rarity of MCC, the
absolute risk remains small, approximately 1 case per 10000
person–years. Most MCCs diagnosed among individuals with CLL
contain MCPyV DNA. A reasonable hypothesis to explain the
association between MCC and CLL is immunosuppression related
to CLL and/or to its treatments, which may favour development of
MCCs, possibly through MCPyV infection. Clinicians who treat
CLL should be aware of the greatly increased risk of MCC, because
MCC can usually be cured by surgery with or without radiation
therapy when detected early, whereas MCC with distant metastases
is currently an invariably fatal disease.
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